Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Author(s): Riepl Mike, Kaiser Joe
Issue: Sep/Oct 2023 - Volume 27, Number 5
View All Articles in Issue
Page(s): 368-380
Download in electronic PDF format for $75
Abstract: The effects of infection with the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus- disease–2019 (COVID-19) it engenders continue to demonstrate that worldwide, the detection, prediction, and control of novel-pathogen pandemics remain largely unattained achievements. Key to successfully meeting those goals is a thorough understanding of the mechanisms of evolving causative agents and effective prophylaxis against them. In this article, we review common conditions that afflict people with COVID-19 or long COVID, examine the effectiveness of vaccines designed to prevent infection with SARS-CoV-2 and mitigate its sequelae, and provide formulations for 2 compounded preparations that can assist recovery from acute and chronic conditions caused by that virus when manufactured drugs are unavailable in required dosages or dosage forms or cannot be tolerated by the patient.
Related Keywords: Mike Riepl, RPh, Joe Kaiser, PharmD, RPh, severe acute respiratory syndrome coronavirus-disease-2019, COVID-19, SARS-CoV-2, pandemics, contagious pathogens, COVID-associated conditions, long COVID, anosmia, hyposmia, ageusia, dysgeusia, sense of smell, sense of taste, chemesthesis changes, loss of taste, loss of smell, mucosal sensitivity, selective serotonin reuptake inhibitors, SSRI, depression, serotonin-norepinephrine reuptake inhibitor, public health measures, mRNA vaccines, naltrexone hydrochloride, formulations, booster vaccinations
Related Categories: EAR NOSE THROAT, FORMULATIONS, ADVERSE DRUG EVENTS, ALLERGY/IMMUNOLOGY/INFLAMMATION, INFECTIOUS DISEASE